Abivax’s €85 Million Funding Round

Dechert advised Abivax on the deal. Abivax, a Euronext Paris listed clinical-stage biotechnology company, executed its oversubscribed capital increase of €60 million and convertible bonds of...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here